AXCA HEALPAR Stock

AXLA

US05454B2043

OTC Markets Traded

Analysts' recommendations : AXCA HEALPAR

22-12-16	HC Wainwright Downgrades Axcella Health to Neutral From Buy	MT
22-12-16	SVB Securities Downgrades Axcella Health to Market Perform From Outperform, Adjusts Price Target to $2 From $6	MT
22-11-02	Chardan Lowers PT for Axcella Health to $5 From $7, Citing 'Greater Dilutionfrom Future Modeled Capital Raises', Maintains Buy Rating	MT
22-10-14	Wedbush Adjusts Axcella Health's Price Target to $6 From $9, Citing Stock Dilution; Outperform Rating Kept	MT
22-10-03	HC Wainwright Adjusts Axcella Health's Price Target to $10 From $8, Maintains Buy Rating	MT

More recommendations

Axcella Health Inc. is a clinical-stage biotechnology company. The Company is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.

Employees

Sector

More about the company

23-11-28	Axcella Health Inc.(NasdaqGM:AXLA) dropped from S&P TMI Index	CI
23-11-23	Axcella Health Inc.(OTCPK:AXLA) dropped from NASDAQ Composite Index	CI
23-11-20	Investors Look Forward to Fed Minutes, Economic Data as Exchange-Traded Funds, Equity Futures Rise Marginally Pre-Bell	MT
23-11-20	Top Premarket Decliners	MT
23-11-01	Axcella Health Inc. Announces Chief Executive Officer Changes	CI
23-11-01	Axcella Health Inc. Appoints Craig R. Jalbert as Principal Financial Officer	CI
23-11-01	Axcella Health Inc. Announces Management Changes	CI
23-09-27	Axcella Health Sinks Premarket Wednesday, Shares Poised for Ninth Decline in 10 Days Following Reverse Stock Split	MT
23-09-22	Axcella Health Slips Premarket Friday, Poised for Seventh Consecutive Day of Declines After Announcing Reverse Stock Split	MT
23-09-21	Correction: --Axcella Health Slumped 8.1% in Premarket Activity Thursday After Sinking 15% in Previous Regular Trading Session	MT
23-09-21	Axcella Health Slumped 8.1% in Premarket Activity Wednesday After Sinking 15% in Previous Regular Trading Session	MT
23-09-15	Top Midday Decliners	MT
23-09-14	Axcella Health to Implement 1-for-25 Reverse Stock Split -- Shares Dive After-Hours	MT

23-09-14	Axcella Announces Reverse Stock Split Effective September 19, 2023	BU
23-09-11	Axcella Health : Submission of Matters to a Vote of Security Holders - Form 8-K	PU
23-09-11	"2023's Stocks to Watch Under $1 Unveiled: VTAK, AXLA, NVOS, MRIN, KAVL	AQ
23-09-05	Penny Stocks Stocks Poised To Pop On News (EPAZ, AXLA, NVOS, IQST)	AQ
23-08-30	CapitalGainsReport: Top Corona Stocks Watchlist (AXLA, BIXT, TOMDF, NVAX, MRNA)	AQ

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/1/23	Margaret Koziel	Sell	Chief Technology Officer	679	0.0009%
2/17/23	William Hinshaw	Free	Chief Executive Officer	275,000	0.3739%
2/17/23	Margaret Koziel	Free	Chief Technology Officer	70,000	0.0952%

AXCA HEALPAR Stock

Stocks

AXLA

US05454B2043

Latest news : AXCA HEALPAR

Analysts' recommendations : AXCA HEALPAR

Press Releases : AXCA HEALPAR

Quotes and Performance

Latest insider transactions

Company Profile